DOCSLIB.ORG

US 2002/0019421 A1 Biberman (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2002001.9421A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0019421 A1 Biberman (43) Pub. Date: Feb. 14, 2002 (54) COMPOSITIONS AND THERAPY FOR Publication Classification SUBSTANCE ADDICTION (51) Int. CI.7. ... A61K 31/44; A61K 9/00 (76) Inventor: Roni Biberman, Tel-Aviv (IL) (52) U.S. Cl. .............................................. 514/343; 424/43 Correspondence Address: Eitan, Pearl, Latzer & Cohen-Zedek (57) ABSTRACT Stal Park Inhibitors of monoamine oxidase used in combination with 2011 Crystal Drive an addictive Substance, or a pharmacological derivative or Arlington, VA 2.2202-3700 (US) analogue thereof, are useful for the treatment of Substance 9 addiction disorders. In particular, the invention discloses (21) Appl. No.: 09/898,027 compositions, and methods of use thereof, comprising Sel egiline and nicotine for the treatment of cigarette SmokerS (22) Filed: Jul. 5, 2001 wishing to abstain. The compositions and methods of use thereof include oral, inhalant, parenteral and transdermal Related U.S. Application Data patch modes of therapy, whereby the subject benefits from the combined effects of a monoamine oxidase inhibitor in (63) Non-provisional of provisional application No. combination with an addictive Substance, or derivative 60/216,366, filed on Jul. 5, 2000. thereof. US 2002/0019421 A1 Feb. 14, 2002 COMPOSITIONS AND THERAPY FOR 0006 The acetylcholine receptors appear to be of two SUBSTANCE ADDICTION general Subtypes, One Subtype appears to have nicotine as an agonist or muscarine as an agonist. Both types of receptor FIELD OF THE INVENTION are found in the central nervous System as well as the autonomic nervous System. 0001. The present invention relates to medicinal compo Sitions and methods of treating Substance addiction, in 0007. Other compounds in addition to cholinergic and particular addiction to nicotine-containing tobacco products, anticholinergic drugs have been tested for the purpose of wherein administration to an addicted subject of inhibitors attenuating withdrawal Symptoms, including craving. These of monoamine oxidase combined with co-administration of include benzodiazepines, dopamine agonists, Serotonin ago an addictive Substance is used to alleviate withdrawal Symp nists, inhibitors of dopamine carboxylase, and inhibitors of toms and to change or eliminate patterns of addictive Serotonin reuptake or of dopamine reuptake. The neurotrans Substance consumption, in particular that due to cigarette mitter dopamine has been shown to be strongly linked to the Smoking, over both short and extended periods of time. internal mechanism of pleasure Sensation mechanism of animal, including human, brains. BACKGROUND OF THE INVENTION 0008 More recently developed strategies have focused 0002 The present disclosure is related to U.S. provisional on the genetic basis of drug addiction, in particular addiction patent application No. 60/216,366, filed on Jul. 5, 2000 and to nicotine. Thus it has been hypothesized that individuals in which is hereby is incorporated herein by reference. The whom nicotine is slowly metabolized are both more likely to Statistical risk of dying from lung cancer in the United States consume fewer cigarettes or not be Smokers at all. Thus has doubled in the past thirty years for male cigarette inhibition of the metabolism of nicotine, through either SmokerS and has quadrupled for female cigarette SmokerS. inhibition of the nicotine degrading enzymes or through Lung cancer has now displaced cardiovascular disease as the inhibition of the Synthesis of nicotine degrading enzymes. Single most important cause of exceSS mortality among 0009 Inhibitors of the intracellular enzyme monoamine Smokers. Yet, about 50 million Americans continue to oxidase (monoamine oxidase) have been traditionally used Smoke. in medical therapies for the treatment of disease of the 0003. The benefits for smoking cessation are many, and central nervous System, in particular depression and Parkin are summarized in a publication entitled “The Health Ben Son's disease. The use of monoamine oxidase inhibitors in efits of Smoking Cessation: A Report of the Surgeon Gen the treatment of addiction, in particular, tobacco product eral, 1990', available from the Office on Smoking and addiction, has been recurrently Suggested although, for lack Health, Center for Disease Control, Rockville, Md. Among of conclusive data, these therapeutic compounds are not the benefits summarized are that within twenty-four hours currently endorsed for this use by the medical establishment. the chance of a heart attack decreases, within about two 0010 Most significantly, despite the introduction of nico weeks to three months lung function increases up to thirty tine replacement therapies, most frequently administered in percent, and in one year the exceSS risk of coronary heart the form of transdermal patch or nicotine gum, addiction to disease becomes half that of a Smoker. tobacco products and the associated increased morbidity and 0004 Smoking cessation programs often address both the mortality continues to be a global epidemic. physiological factor and the psychological factor. The widely available "nicotine-releasing patches' have been SUMMARY OF THE INVENTION highly advertised, and are useful for maintaining a nicotine 0011. The invention provides a pharmaceutical composi habituated patient on nicotine while addressing further the psychological factors of addiction. Craving is the most tion comprising an amount of an inhibitor of monoamine consistently observed withdrawal symptom and is probably oxidase, an amount of an addictive Substance, or derivative best described as a combination of physiological and psy thereof, and a Suitable diluent or carrier. chological factors. To treat craving for nicotine, other modes 0012. The invention provides a pharmaceutical compo of nicotine replacement therapy have been introduced, Sition comprising an amount of an inhibitor of monoamine including administration of nicotine by oral chewing gum oxidase, an amount of an addictive Substance, or derivative and by inhalation with a carrier for absorption through the thereof, and a Suitable diluent or carrier, wherein Said respiratory mucosa, including the lungs. composition is adapted to administer both the inhibitor of 0005. In addition to nicotine replacement therapy, other monoamine oxidase and the addictive Substance, or deriva pharmacological therapies have been described based on tive thereof, via the same route of administration. compounds which are expected to influence the physiologi 0013 The invention provides a pharmaceutical compo cal mechanisms common to nicotinic agents. This is the Sition comprising an amount of an inhibitor of monoamine basis for the use of compounds which interact with acetyl oxidase, an amount of an addictive Substance or derivative choline receptors, or affect levels of the neurotransmitter thereof, and a Suitable diluent or carrier, wherein Said carrier acetylcholine, as a means for reducing the desire for nicotine is an oral tablet, capsule, a comestible article, an aerosol, or other addictive drugs. Atropine and Scopolamine are nebulized vapor, Smoke, or a transdermal patch, and wherein alkaloids that block the action of acetylcholine at muscarinic Said carrier is Suitable for parenteral administration, includ receptors to produce antispasmodic, antisecretory, and anti ing intradermal, Subcutaneous, intramuscular, intravenous, parkinsonism actions. PhySoStigmine is an inhibitor of the intrathecal, Sublingual, rectal, vaginal, intraocular, transder enzyme acetylcholinesterase, thereby raising the level of mal, respiratory mucosal, or pulmonary routes of adminis acetylcholine through inhibition of its metabolism. tration. US 2002/0019421 A1 Feb. 14, 2002 0.014. The invention provides a pharmaceutical compo PharmaProjects 2806; PharmaProjects 1122; Phar Sition comprising an amount of an inhibitor of monoamine maProjects 331; PharmaProjects 4433; RS-2232; UP-614 oxidase, an amount of an addictive Substance or derivative 04, or mixtures thereof. thereof, and a Suitable diluent or carrier, wherein Said 0018. The invention provides a pharmaceutical compo addictive Substance, or derivative thereof, is nicotine and Sition, wherein Said monoamine oxidase inhibitor is Sel Said carrier is an oral tablet, capsule, a comestible article, an egiline, Said carrier is an oral tablet, a capsule, a comestible aeroSol carrier a vapor, a Smoke, or a transdermal patch and article, an aeroSol, a vapor, a Smoke, or a transdermal patch, wherein Said carrier is Suitable for parenteral administration, and wherein Said carrier is Suitable for parenteral adminis including intradermal, Subcutaneous, intramuscular, intrave tration, including intradermal, Subcutaneous, intramuscular, nous, intrathecal, Sublingual, rectal, vaginal, intraocular, intravenous, intrathecal, Sublingual, rectal, vaginal, transdermal, respiratory mucosal, or pulmonary routes of intraocular, transdermal, respiratory mucosal, or pulmonary administration, routes of administration, and Said addictive Substance, or 0.015 The invention provides a pharmaceutical compo derivative thereof, is nicotine, cotinine, a nicotinic agonist, Sition comprising an amount of an inhibitor of monoamine a derivative of nicotine, a dopamine agonist, an opiate, oxidase, an amount of an addictive Substance or derivative morphine, heroin, methadone, buprenorphine, fentanyl, thereof, and a Suitable diluent or carrier, wherein Said i naloxone, codeine, an amphetamine,
Recommended publications
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway

    Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway

    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
  • Experimental Dopamine Reuptake Inhibitors in Parkinson’S Disease: a Review of the Evidence

    Experimental Dopamine Reuptake Inhibitors in Parkinson’S Disease: a Review of the Evidence

    Journal of Experimental Pharmacology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence This article was published in the following Dove Press journal: Journal of Experimental Pharmacology Thomas Müller Abstract: Parkinson’s disease (PD) is the second most chronic neurodegenerative disorder worldwide. Deficit of monoamines, particularly dopamine, causes an individually varying Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, compilation of motor and non-motor features. Constraint of presynaptic uptake extends 13088, Germany monoamine stay in the synaptic cleft. This review discusses possible benefits of dopamine reuptake inhibition for the treatment of PD. Translation of this pharmacologic principle into positive clinical study results failed to date. Past clinical trial designs did not consider a mandatory, concomitant stable inhibition of glial monoamine turnover, i.e. with mono­ amine oxidase B inhibitors. These studies focused on improvement of motor behavior and levodopa associated motor complications, which are fluctuations of motor and non-motor behavior. Future clinical investigations in early, levodopa- and dopamine agonist naïve patients shall also aim on alleviation of non-motor symptoms, like fatigue, apathy or cognitive slowing. Oral levodopa/dopa decarboxylase inhibitor application is inevitably necessary with advance of PD. Monoamine reuptake (MRT) inhibition improves the efficacy of levodopa, the blood brain barrier crossing metabolic precursor of dopamine. The pulsatile brain delivery pattern of orally administered levodopa containing formulations results in synaptic dopamine variability. Ups and downs of dopamine counteract the physiologic principle of continuous neurotransmission, particularly in nigrostriatal, respectively meso­ corticolimbic pathways, both of which regulate motor respectively non-motor behavior.
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions

    Ayahuasca: Spiritual Pharmacology & Drug Interactions

    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
  • National Center for Toxicological Research

    National Center for Toxicological Research

    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar

    United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar

    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
  • NIH Public Access Author Manuscript Neuroscience

    NIH Public Access Author Manuscript Neuroscience

    NIH Public Access Author Manuscript Neuroscience. Author manuscript; available in PMC 2016 January 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuroscience. 2015 January 22; 0: 775–797. doi:10.1016/j.neuroscience.2014.10.044. Early-life Exposure to the SSRI Paroxetine Exacerbates Depression-like Behavior in Anxiety/Depression-prone rats Matthew E. Glover1, Phyllis C. Pugh1, Nateka L. Jackson1, Joshua L. Cohen1, Andrew D. Fant2, Huda Akil3, and Sarah M. Clinton1,§ 1Department of Psychiatry and Behavioral Neurobiology, University of Alabama-Birmingham, USA 2Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA 3Molecular and Behavioral Neuroscience Institute, University of Michigan, USA Abstract Selective serotonin reuptake inhibitor (SSRI) antidepressants are the mainstay treatment for the 10–20% of pregnant and postpartum women who suffer major depression, but the effects of SSRIs on their children’s developing brain and later emotional health are poorly understood. SSRI use during pregnancy can elicit antidepressant withdrawal in newborns and increase toddlers’ anxiety and social avoidance. In rodents, perinatal SSRI exposure increases adult depression- and anxiety- like behavior, although certain individuals are more vulnerable to these effects than others. Our study establishes a rodent model of individual differences in susceptibility to perinatal SSRI exposure, utilizing selectively-bred Low Responder (bLR) and High Responder (bHR) rats that were previously bred for high versus low behavioral response to novelty. Pregnant bHR/bLR females were chronically treated with the SSRI paroxetine (10 mg/kg/day p.o.) to examine its effects on offspring’s emotional behavior and gene expression in the developing brain.
  • Protocol/Amendment No.: 252-10 a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combin

    Protocol/Amendment No.: 252-10 a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combin

    Product: MK-3475 (SCH 900475), INCB024360 1 Protocol/Amendment No.: 252-10 (INCB 24360-301-10) / NCT02752074 THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. This study is co-funded by Incyte and MSD. Execution of Trial: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. One Merck Drive P.O. Box 100 Whitehouse Station, New Jersey, 08889-0100, U.S.A. Protocol-specific Contact information can be found in the Investigator Trial File Binder (or equivalent). Global Sponsor of the Study: Incyte Corporation (Referenced herein as Sponsor) 1801 Augustine Cut-Off Wilmington, Delaware, 19803, U.S.A TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK- 3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (KEYNOTE-252 / ECHO-301) IND NUMBER: 121,704 EudraCT NUMBER: 2015-004991-31 MK-3475-252-10 (INCB 24360-301-10) Final Protocol 18-May-2018 Confidential 04XN7M Product: MK-3475 (SCH 900475), INCB024360 2 Protocol/Amendment No.: 252-10 (INCB 24360-301-10) TABLE OF CONTENTS SUMMARY OF CHANGES.................................................................................................14 1.0 TRIAL SUMMARY...................................................................................................29 2.0 TRIAL DESIGN.........................................................................................................30
  • Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report

    Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report

    CASE REPORT Journal of Psychedelic Studies 3(1), pp. 7–13 (2019) DOI: 10.1556/2054.2019.001 First published online February 12, 2019 Long-lasting analgesic effect of the psychedelic drug changa: A case report GENÍS ONA1* and SEBASTIÁN TRONCOSO2 1Department of Anthropology, Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona, Spain 2Independent Researcher (Received: August 23, 2018; accepted: January 8, 2019) Background and aims: Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa,a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods: We describe the case and offer a brief review of supportive findings. Results: A long-lasting analgesic effect after the use of changa was reported. Possible analgesic mechanisms are discussed. We suggest that both pharmacological and non-pharmacological factors could be involved. Conclusion: These findings offer preliminary evidence of the analgesic effect of changa, but due to its complex pharmacological actions, involving many neurotransmitter systems, further research is needed in order to establish the specific mechanisms at work. Keywords: analgesic, pain, psychedelic, psychoactive, DMT, β-carboline alkaloids INTRODUCTION effects of ayahuasca usually last between 3 and 5 hr (McKenna & Riba, 2015), but the effects of smoked changa – The treatment of pain is one of the most significant chal- last about 15 30 min (Ott, 1994). lenges in the history of medicine. At present, there are still many challenges that hamper pain’s appropriate treatment, as recently stated by American Pain Society (Gereau et al., CASE DESCRIPTION 2014).
  • Inhibition of Monoamine Oxidase in 5

    Inhibition of Monoamine Oxidase in 5

    Br. J. Pharmac. (1985), 85, 683-690 Inhibition ofmonoamine oxidase in 5- hydroxytryptaminergic neurones by substitutedp- aminophenylalkylamines Anna-Lena Ask, Ingrid Fagervall, L. Florvall, S.B. Ross1 & Susanne Ytterborn Research Laboratories, Astra Likemedel AB, S-151 85 Si3dertilje, Sweden 1 A series ofsubstituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition ofmonoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptamin- ergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence ofcitalopram using a low (0.1 yIM) concentration of ['4CJ-5-hydroxytryptamine (5-HT) as substrate. 2 Some ofthe phenethylamines were much more potent inside than outside the 5-hydroxytryptamin- ergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. 3 Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5- positions decreased both potency and selectivity. 4 Prolongation ofthe side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained.